Global Peptide Drug Sales Ranking in the First Half of 2025 (Market Driven by Peptide Synthesis Technology)
Publish Time:
2025-08-28
In the first half of 2025, the global peptide drug market is highly competitive. Breakthroughs in peptide drug synthesis technology (such as long-acting modifications and dual receptor agonist design) continue to drive GLP-1 class and its derivative drugs to lead the market, while classic peptide drugs like radioligand therapy and somatostatin analogs remain solid in niche areas. The following are core data and market highlights (insulin class not included):
1. 2025H1 Global Peptide Drug Sales TOP15 (Simplified Version)
| Drug Name | Active Ingredient (API) | Developer | Core Indications | 2025H1 Sales (Billion USD) | Year-on-Year Change | Key Advantages (Related to Peptide Drug Synthesis) |
|---|---|---|---|---|---|---|
| Ozempic | Semaglutide (司美格鲁肽) | Novo Nordisk | Type 2 Diabetes, Cardiovascular Disease, Chronic Kidney Disease | 101.06 | +15% | Peptide drug synthesis with C18 fatty acid modification, enabling once-weekly injection |
| Mounjaro | Tirzepatide (替尔泊肽) | Eli Lilly | Type 2 Diabetes | 90.41 | +84% | First peptide drug synthesis GIP/GLP-1 dual receptor agonist |
| Wegovy | Semaglutide (司美格鲁肽) | Novo Nordisk | Obesity, Cardiovascular Disease | 57.78 | +78% | Optimized peptide drug synthesis, received FDA accelerated approval for MASH (Metabolic Associated Steatohepatitis) |
| Zepbound | Tirzepatide (替尔泊肽) | Eli Lilly | Obesity, Obstructive Sleep Apnea | 56.93 | +223% | Outstanding weight loss effect based on peptide drug synthesis, entered top ranks within less than 2 years on market |
| Trulicity | Dulaglutide (度拉糖肽) | Eli Lilly | Type 2 Diabetes, Cardiovascular Disease | 21.87 | -19% | Early peptide drug synthesis achievement, maintains sales relying on injection convenience |
| Rybelsus | Semaglutide (司美格鲁肽) | Novo Nordisk | Type 2 Diabetes | 17.77 | +5% | First oral peptide drug synthesis GLP-1 (with SNAC absorption enhancer) |
| Somatuline | Lanreotide (兰瑞肽) | Ipsen | Acromegaly, Gastroenteropancreatic Neuroendocrine Tumors | 15.06 | +6% | Long-acting peptide drug synthesis somatostatin analog |
| Paxlovid | Nirmatrelvir/Ritonavir | Pfizer | COVID-19 Infection | 9.18 | -60% | Peptide antiviral drug, demand declined post-pandemic |
| Pluvicto | Lutetium Lu 177 vipivotide tetraxetan | Novartis | Metastatic Castration-Resistant Prostate Cancer | 8.25 | +26% | Peptide drug synthesis ligand + 177Lu radionuclide, representative of radioligand therapy |
| Kyprolis | Carfilzomib (卡非佐米) | Amgen | Multiple Myeloma | 7.02 | -7% | Second-generation peptide drug synthesis proteasome inhibitor |
| Sandostatin | Octreotide (奥曲肽) | Novartis | Acromegaly, Gigantism | 6.20 | -6% | Classic peptide drug synthesis somatostatin analog, facing competition from similar drugs |
| Zoladex | Goserelin (戈舍瑞林) | AstraZeneca | Prostate Cancer, Breast Cancer | 5.87 | +5% | Long-acting peptide drug synthesis GnRH agonist, on market for over 30 years |
| Gattex/Revestive | Teduglutide (替度鲁肽) | Takeda Pharmaceutical | Short Bowel Syndrome | 4.61 | +3% | Peptide drug synthesis GLP-2 analog, improves intestinal absorption |
| Linzess/Constella | Linaclotide (利那洛肽) | Ironwood / AbbVie | Chronic Idiopathic Constipation, Irritable Bowel Syndrome | 4.06 | -17% | Peptide guanylate cyclase C agonists, affected by medical insurance cost control |
| Lutathera | Lutetium Lu 177 dotatate | Novartis | Gastroenteropancreatic neuroendocrine tumors | 4.00 | +16% | Drug peptide synthesis ligand + 177Lu, core asset of radioligand therapy |
II. Core Market Trends (Related to Drug Peptide Synthesis)
GLP-1 class becomes the absolute main force: Upgrades in drug peptide synthesis technology (such as long-acting modifications, dual receptor design) allow products like Ozempic and Mounjaro to rank among the top 4 in sales, continuously breaking through in diabetes, weight loss, and metabolic liver disease fields.
Steady progress in niche areas: Radioligand therapy (such as Pluvicto, Lutathera) and somatostatin analogs (such as Somatuline) rely on drug peptide synthesis and radionuclide/receptor targeting binding technology, maintaining demand in tumors and endocrine diseases.
Older products face iteration: Early peptide drugs like Victoza (liraglutide) and Saxenda (liraglutide), due to outdated drug peptide synthesis technology (e.g., daily injections), are replaced by new generation weekly and oral formulations, with sales declining over 50% year-on-year.
III. Key Conclusions
In the first half of 2025, the innovation level of drug peptide synthesis technology directly determines product competitiveness in the peptide drug market: leading companies seize the market by optimizing peptide structures (such as modifications, dual receptor design) and expanding administration routes (oral, long-acting injections); classic varieties need to rely on technology upgrades or niche indications to maintain share. In the future, the combination of drug peptide synthesis with targeted therapy and radionuclide conjugation will further promote the application of peptide drugs in more disease areas.
Relevant Information
undefined
